85 related articles for article (PubMed ID: 20561423)
1. [Anti-CD20 monoclonal antibody RTX enhances radiosensitivity of lymphoma cells].
Min FL; Liu FJ; Wen WX; Zhai LJ; Zhou W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):660-5. PubMed ID: 20561423
[TBL] [Abstract][Full Text] [Related]
2. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P
J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145
[TBL] [Abstract][Full Text] [Related]
3. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
Skvortsova I; Popper BA; Skvortsov S; Saurer M; Auer T; Moser R; Kamleitner H; Zwierzina H; Lukas P
J Radiat Res; 2005 Jun; 46(2):241-8. PubMed ID: 15988143
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical study of apoptosis of B-NHL cell lines induced by anti-CD20 monoclonal antibody].
Zhang HY; Chen HT; Guan ZZ; Huang Y; Zhang X; Lin TY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):883-7. PubMed ID: 19698222
[TBL] [Abstract][Full Text] [Related]
6. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
Lara S; Heilig J; Virtanen A; Kleinau S
BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
[TBL] [Abstract][Full Text] [Related]
7. [Biological response of B-cell lymphoma cells in vitro to 131I-rituximab].
Wei L; Luo RC; Zhang JY; Yan X; Fang YX; Fei LH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):211-3. PubMed ID: 16503532
[TBL] [Abstract][Full Text] [Related]
8. Influx of extracellular calcium participates in rituximab-enhanced ionizing radiation-induced apoptosis in Raji cells.
Fengling M; Qingxiang G; Lijia Z; Wei Z
Toxicol Lett; 2012 Mar; 209(3):221-6. PubMed ID: 22245670
[TBL] [Abstract][Full Text] [Related]
9. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab.
Daniels I; Turzanski J; Haynes AP
Br J Haematol; 2008 Jul; 142(3):394-403. PubMed ID: 18544085
[TBL] [Abstract][Full Text] [Related]
10. Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
Singh V; Gupta D; Arora R; Tripathi RP; Almasan A; Macklis RM
PLoS One; 2014; 9(11):e111113. PubMed ID: 25364827
[TBL] [Abstract][Full Text] [Related]
11. Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels.
Nozaki Y; Mitsumori T; Yamamoto T; Kawashima I; Shobu Y; Hamanaka S; Nakajima K; Komatsu N; Kirito K
Exp Hematol; 2013 Aug; 41(8):687-696.e1. PubMed ID: 23603515
[TBL] [Abstract][Full Text] [Related]
12. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
14. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
16. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
17. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].
Liu YX; Fan DM; Xiong DS; Xu YF; Shao XF; Xu YS; Peng H; Yang M; Qin L; Zhu ZP; Yang CZ
Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
19. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab-mediated sensitization of B-NHL cell lines to apoptosis induced by gemcitabine and Navelbine in vitro].
Zhang HY; Chen HT; Peng PJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):873-6. PubMed ID: 20723291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
